Page 1

ANTERIS ASX ANNOUNCEMENT 22 April 2021 QUARTERLY ACTIVITY REPORT FOR THE PERIOD TO 31 MARCH 2021 Anteris Technologies Ltd ( ASX : AVR ) ( Anteris or " the Company " ) releases its Appendix 4C - Quarterly Cash Flow report and commentary for the quarter ended 31 March 2021 ( Q1 , 2021 ) . Highlights • • • Major progress made towards planned US TAVR clinical study for later this year . The Company's anti - calcification study showed the superior performance of Anteris ' ADAPTⓇ treated tissue compared with tissues used in competitor valves . First - in - human SAVR ( Surgical Aortic Valve Replacement ) trial continues to progress despite the ongoing COVID - 19 pandemic in Europe . FDA Early Feasibility Study pre - submission meeting . Full catheter delivery system tests and simulations completed ( successful deployment of steerable balloon catheter ) . A $ 20m funding package established with Mercer Street Global Opportunity Fund , LLC ( Mercer ) , realising an initial $ 2.5M with a further $ 4.05M realised ( pre - transaction costs ) early in Q2 2021 . $ 1.6M of revenue , primarily derived by manufacturing for LeMaitre Vascular , Inc. COMMENTARY ON THE QUARTER During the quarter , Anteris made major progress towards its planned US submission and approval of the clinical study scheduled for later this year . Continued success in its clinical and pre - clinical studies as well as growing KOL enthusiasm for its prosthetic aortic valve replacement solutions underpins the Company's ambitious development program . Anteris reported positive results from its anti - calcification study , where its ADAPTⓇ treated tissue showed superior anti - calcification attributes compared with tissues used in competitor valves . Based on these results , the Company plans a further study comparing the ADAPTⓇ tissue with both Medtronic's AOATM and Edwards Life Science's ResiliaⓇ . ResiliaⓇ is Edwards ' next generation tissue treatment for its valves . The consequent head - to - head study is expected to commence later this year . Anteris Technologies Ltd Registered Office : Toowong Tower , Suite 302 , Level 3 , 9 Sherwood Rd , Toowong , Queensland , 4066 Customer Service T +61 1300 550 310 | F +61 1300 972 437 | E info@anteristech.com | W anteristech.com Brisbane Minneapolis ▪ Geneva ▪ Malaga • ADAPT for life